- Home
- EML vs FATE Comparison
EML vs FATE Comparison
Compare EML & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- FATE
- Stock Information
- Founded
- EML 1858
- FATE 2007
- Country
- EML United States
- FATE United States
- Employees
- EML N/A
- FATE N/A
- Industry
- EML Industrial Machinery/Components
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- FATE Health Care
- Exchange
- EML Nasdaq
- FATE Nasdaq
- Market Cap
- EML 144.5M
- FATE 130.7M
- IPO Year
- EML N/A
- FATE 2013
- Fundamental
- Price
- EML $21.52
- FATE $1.09
- Analyst Decision
- EML
- FATE Hold
- Analyst Count
- EML 0
- FATE 7
- Target Price
- EML N/A
- FATE $3.58
- AVG Volume (30 Days)
- EML 9.1K
- FATE 1.6M
- Earning Date
- EML 08-05-2025
- FATE 08-12-2025
- Dividend Yield
- EML 2.04%
- FATE N/A
- EPS Growth
- EML N/A
- FATE N/A
- EPS
- EML N/A
- FATE N/A
- Revenue
- EML $269,054,445.00
- FATE $8,470,000.00
- Revenue This Year
- EML $1.56
- FATE N/A
- Revenue Next Year
- EML $7.00
- FATE N/A
- P/E Ratio
- EML $12.04
- FATE N/A
- Revenue Growth
- EML 1.30
- FATE N/A
- 52 Week Low
- EML $19.06
- FATE $0.66
- 52 Week High
- EML $35.03
- FATE $4.20
- Technical
- Relative Strength Index (RSI)
- EML 38.49
- FATE 49.33
- Support Level
- EML $22.21
- FATE $0.91
- Resistance Level
- EML $24.28
- FATE $1.24
- Average True Range (ATR)
- EML 0.69
- FATE 0.09
- MACD
- EML -0.01
- FATE 0.00
- Stochastic Oscillator
- EML 0.72
- FATE 42.86
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.